SYGNIS announces completion of Sales and Marketing team restructuring to support continued strong revenue growth

Heidelberg, Germany and Cambridge, UK, 15 March 2018 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard), today announced the restructuring of its sales and marketing team to drive continued strong revenue growth. A direct sales and distribution team focused on product sales has been formed while a business development team will focus on partnering and service opportunities. Both teams will be supported by marketing, responsible for maintaining the recently launched integrated Expedeon branded product website to drive strong lead and sales opportunity generation, as well as wider group marketing activities.

Acquisitions continue to make a major contribution to the year on year revenue growth from EUR 1.8 million in 2016 to EUR 7.8 million (unaudited) in 2017. Alongside this, our organic growth, a cornerstone of our ‘grow, buy, build strategy’, continued apace with year on year like for like growth of 24%, underpinned by our strong sales and marketing team.
These changes in the team follow significant expansion in the past year to well over 30 employees. The reorganisation will continue to support future strong revenue growth with our team focusing on delivering outstanding organic growth across our product and service portfolio.

Dr. Heikki Lanckriet, CEO and CSO of Sygnis AG commented: “We continue to focus on our ‘grow, buy, build strategy’ which has driven exciting revenue growth underpinned by a strong sales and marketing function. These changes were necessary to ensure we exploit the many commercial opportunities arising across our portfolio of products and technologies and which is supported by our very strong sales and marketing team. These building blocks have delivered year on year revenue growth including our benchmark organic growth.”

SYGNIS develops and commercialises value-added, easy-to-use, reliable products for genomics and proteomics research based on its proprietary technologies, offering a wide range of solutions that address key challenges in molecular biology. With applications spanning the entire molecular biology workflow, the Group’s cutting-edge offerings include easy-to-use off-the-shelf products as well as custom services, supporting scientists from academia through to commercial manufacturing. SYGNIS’ products are sold through a direct sales force and several distribution partners in Europe, the USA and Asia. SYGNIS AG has offices in Germany, Spain, UK, USA and Singapore which trade under the Expedeon brand. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: LIO1; ISIN: DE000A1RFM03).